The CAMELIA study (6), a large randomised clinical trial investigating the mortality impact of early antiretroviral therapy (ART) in TB–HIV co-infected patients, enrolled HIV-infected adults with CD4 count <200/mm3 and a first episode of pulmonary or extra-pulmonary TB. The gene discussed is CD4; the disease is tuberculosis.